文献速递肿瘤 PET/CT神经核医学

18F-AlF-NOTA-奥曲肽PET/CT联合18F-FDG PET/CT用于神经内分泌肿瘤显像的临床应用

Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms.
PubMed 文献 · Clin Nucl Med · 2019-01-01

18F-OC耐受良好,有效剂量为0.023±0.002 mSv/MBq;18F-OC肿瘤摄取高于18F-FDG,在G2 NEN中尤为明显(中位SUVmax 45.6 vs 4.3,P<0.015)。双示踪剂PET/CT检出更多病灶并提供肿瘤生物学状态信息。

要点

  • 18F-OC耐受良好,有效剂量为0.023±0.002 mSv/MBq。
  • 18F-OC肿瘤摄取高于18F-FDG,G2 NEN中位SUVmax 45.6 vs 4.3(P<0.015)。
  • 双示踪剂PET/CT可检出更多病灶并反映肿瘤生物学状态。

核心结论

  • 18F-OC安全性及剂量学表现良好,对高分化NEN显像优于18F-FDG,双示踪剂PET/CT有助改善NEN分期与治疗管理。

研究设计与样本

  • 在3名健康志愿者中评估18F-OC生物分布、剂量学和安全性。

主要发现

  • 18F-OC在健康志愿者和NEN患者中均耐受良好。
  • NEN患者中观察到显著的18F-OC肿瘤摄取和高肿瘤/本底比值。
  • 18F-OC肿瘤摄取高于18F-FDG,在G2 NEN中尤为明显(中位SUVmax 45.6 vs 4.3;P<0.015)。
  • 18F-OC或18F-FDG肿瘤摄取与肿瘤分化程度显著相关(P<0.05)。
  • 双示踪剂PET/CT检出更多病灶并提供肿瘤生物学状态信息。

关键数值与推荐

  • 18F-OC计算有效剂量为0.023±0.002 mSv/MBq。
  • 18F-OC注射剂量为3.7至4.44 MBq/kg(0.1-0.12 mCi/kg),注射后60分钟行PET/CT。
  • G2 NEN中18F-OC与18F-FDG中位SUVmax分别为45.6与4.3(P<0.015)。

临床怎么用

  • 对高分化NEN可优先考虑18F-OC PET/CT显像。
  • 联合18F-FDG与18F-OC双示踪剂PET/CT有助于改善NEN分期和指导治疗管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study is to evaluate biodistribution, dosimetry, safety, and clinical usefulness of F-AlF-NOTA-octreotide (F-OC) PET/CT in combination with F-FDG PET/CT for detection of neuroendocrine neoplasms (NENs). METHODS: The biodistribution, dosimetry, and safety of F-OC were evaluated in 3 healthy volunteers. Twenty-two NEN patients underwent PET/CT at 60 minutes after intravenous injection of 3.7 to 4.44 MBq (0.1-0.12 mCi) per kilogram of body weight of F-OC. This was followed by F-FDG PET/CT within a 2-week period. RESULTS: F-OC was well tolerated by all healthy volunteers and NEN patients. The calculated effective dose of F-OC was 0.023 ± 0.002 mSv/MBq. In NEN patients, we observed prominent F-OC tumor uptake and high tumor-to-background ratios. Tumor uptake of F-OC was greater than that of F-FDG, and this was particularly evident in G2 NENs (median SUVmax, 45.6 vs 4.3; P < 0.015). Tumor uptake of F-OC or F-FDG was significantly correlated with tumor differentiation (P < 0.05). Dual tracer PET/CT detected more lesions and also yielded information on the biological status of tumors. CONCLUSIONS: The tracer F-OC exhibited favorable safety and dosimetry profiles. F-OC provided superior imaging of well-differentiated NENs and significantly higher tumor-to-background ratio compared with F-FDG. Combining F-FDG with F-OC PET/CT has the potential to improve NEN staging and management of patient treatment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Long T, Yang N, Zhou M, et al. Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms. Clin Nucl Med. 2019. PMID: 30985413. doi:10.1097/RLU.0000000000002578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。